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Idiopathic pulmonary fibrosis (IPF) is a chronic, fibrosing interstitial lung disease that primarily affects older adults.
Median survival after diagnosis is 2–3 years. The clinical course of IPF may include periods of acute deterioration in
respiratory function, which are termed acute exacerbations of IPF (AEx-IPF) when a cause cannot be identified.
AEx-IPF may represent a sudden acceleration of the underlying disease process of IPF, or a biologically distinct
pathological process that is clinically undiagnosed. An AEx-IPF can occur at any time during the course of IPF and
may be the presenting manifestation. The incidence of AEx-IPF is hard to establish due to variation in the
methodology used to assess AEx-IPF in different studies, but AEx-IPF are believed to occur in between 5 and 10%
of patients with IPF every year. Risk factors for AEx-IPF are unclear, but there is evidence that poorer lung function
increases the risk of an AEx-IPF and reduces the chances of a patient surviving an AEx-IPF. The presence of
comorbidities such as gastroesophageal reflux disease (GERD) and pulmonary hypertension may also increase the
risk of an AEx-IPF. AEx-IPF are associated with high morbidity and mortality. Patients who experience an AEx-IPF
show a worsened prognosis and AEx-IPF are believed to reflect disease progression in IPF. Current treatments for
AEx-IPF have only limited data to support their effectiveness. The latest international treatment guidelines state that
supportive care remains the mainstay of treatment for AEx-IPF, but also give a weak recommendation for the
treatment of the majority of patients with AEx-IPF with corticosteroids. There is emerging evidence from clinical
trials of investigational therapies that chronic treatment of IPF may reduce the incidence of AEx-IPF. Additional
clinical trials investigating this are underway.
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Idiopathic pulmonary fibrosis (IPF) is a chronic, fibrosing
interstitial pneumonia of unknown cause that occurs pri-
marily in older adults [1]. In the United States, the inci-
dence of IPF has been estimated to be between 6.8 and 8.8
cases per 100,000 person years using narrow case defini-
tions, and between 16.3 and 17.4 cases per 100,000 person
years using broad case definitions [2]. IPF is rare in patients
under 50 years, with patients typically presenting in their
fifties or sixties [1]. The prognosis of IPF is poor, with a me-
dian survival time after diagnosis of 2 to 3 years [3]; death
generally occurs as a result of progressive respiratory failure
[1,4]. However, the course of IPF is highly variable. Some
patients progress rapidly, others much more slowly, while
some patients experience periods of relative stability punc-
tuated by acute deteriorations in respiratory functionCorrespondence: dskim615@gmail.com
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reproduction in any medium, provided the or(Figure 1) [1,4,5]. If a cause of this deterioration cannot be
identified (e.g. infection, pulmonary embolism), this deteri-
oration is termed an acute exacerbation of IPF (AEx-IPF)
[1,6]. This review focuses on the evidence on the impact,
management and possible prevention of AEx-IPF.Definition of AEx-IPF
A universally agreed definition of an AEx-IPF has not
been established. Clinical studies have used a variety of
criteria to define AEx-IPF, which differ in factors such as
whether chest X-ray, or high-resolution computed tom-
ography (HRCT) is required, how hypoxemia is defined,
and the conditions that must be ruled out [7-14]. Vari-
ation in the definitions and methodology used to assess
AEx-IPF has complicated researchers’ and physicians’
understanding of AEx-IPF and their impact.
In 2007, a consensus definition for AEx-IPF was pro-
posed by an expert committee sponsored by the IPFis an Open Access article distributed under the terms of the Creative Commons
rg/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Figure 1 Schematic representation of clinical disease courses in patients with IPF. There are several possible disease courses in patients
with IPF. Patients may experience rapid disease progression (line A) or a much more gradual progression of disease (line C), while some patients
exhibit periods of relative stability punctuated by periods of acute worsening (stars) (line B). Where the cause of the acute deterioration cannot
be identified, the deterioration is termed an acute exacerbation of IPF. Reproduced from Ley B, Collard HR, King TE Jr: Clinical course and
prediction of survival in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2011, 183:431–440. Reprinted with permission of the
American Thoracic Society. Copyright © 2013 American Thoracic Society.
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Lung and Blood Institute (NHLBI), in an attempt to
standardize the diagnostic criteria used across studies
[6]. This committee defined AEx-IPF as an acute,
clinically significant deterioration of unidentifiable
cause and proposed five diagnostic criteria (Table 1)
[6]. This definition has become the most widely used
definition of AEx-IPF and has been used in several
clinical studies [13,15-19].Table 1 Diagnostic criteria for AEx-IPF
1 Previous or concurrent diagnosis of IPF†
2 Unexplained worsening or development of dyspnea within 30 days
3 HRCT with new bilateral ground-glass abnormality and/or consolidation s
consistent with UIP pattern‡
4 No evidence of pulmonary infection by endotracheal aspirate or BAL§
5 Exclusion of alternative causes, including:
• Left heart failure
• Pulmonary embolism
• Identifiable cause of acute lung injury¶
†If the diagnosis of IPF is not previously established according to American Thoracic
met by the presence of radiologic and/or histopathologic changes consistent with U
qualifier “new” can be dropped. §Evaluation of samples should include studies for r
pathogens. ¶Causes of acute lung injury include sepsis, aspiration, trauma, reperfusi
injury, cardiopulmonary bypass, drug toxicity, acute pancreatitis, transfusion of bloo
Reproduced from Collard HR, et al.: Acute exacerbations of idiopathic pulmonary
permission of the American Thoracic Society. Copyright © 2013 American ThoracicIncidence of AEx-IPF
The true incidence of AEx-IPF remains unclear.
Reported incidences vary widely across studies, due to
the lack of a consistent definition and differences in
study methodology and patient selection [20,21]. The
most recent international guidelines, issued jointly
by the American Thoracic Society (ATS), European
Respiratory Society (ERS), Japanese Respiratory Society
(JRS) and Latin American Thoracic Association (ALAT)uperimposed on a background reticular or honeycomb pattern
Society/European Respiratory Society consensus criteria, this criterion can be
IP pattern on the current evaluation. ‡If no previous HRCT is available, the
outine bacterial organisms, opportunistic pathogens, and common viral
on pulmonary edema, pulmonary contusion, fat embolization, inhalational
d products, and stem cell transplantation.
fibrosis. Am J Respir Crit Care Med 2007, 176:636–643. Reprinted with
Society.
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IPF occurs in approximately 5–10% of patients with di-
agnosed IPF annually [1]. A recent retrospective study of
data collected from 461 patients with diagnosed IPF
found 1-year and 3-year incidences of AEx-IPF of 14.2%
and 20.7%, respectively [19]. However, the incidence
rates of AEx-IPF reported in clinical trials have tended
to be lower than this.
Pathophysiology of AEx-IPF
A variety of patterns of acute lung injury have been ob-
served in AEx-IPF [22]. The most common histopatho-
logical finding is diffuse alveolar damage superimposed
on the underlying usual interstitial pneumonia
(UIP) pattern [6,8,9,11,12,23,24], but organizing pneu-
monia and extensive fibroblastic foci have also been
reported [22].
Several hypotheses for the etiology of AEx-IPF have
been proposed. AEx-IPF may represent a sudden accel-
eration of the underlying disease process due to un-
known acute injury to the lung, or a biologically distinct
pathological process due to a clinically occult condition,
such as infection or gastroesophageal reflux disease
(GERD) [6]. As AEx-IPF have a clinical presentation that
shares a number of features with viral respiratory infec-
tions (e.g. fever, cough, myalgia), it has been suggested
that occult viral infection may contribute to the patho-
physiology of AEx-IPF [20,25,26]. However, the evidence
supporting the involvement of viral infections in AEx-
IPF is mixed [1,20,25]. The most recent and extensive
study, which used genomic-based technologies to inves-
tigate the role of viruses in the etiology of AEx-IPF,
suggested that viral infection is not a common cause of
AEx-IPF [27].
Although research is ongoing into gene expression
patterns and the identification of biomarkers, the mo-
lecular mechanisms underlying AEx-IPF remain poorly
understood. Activation of the immune system, disor-
dered coagulation/fibrinolysis, and oxidative stress may
all contribute to the pathophysiology of AEx-IPF. Im-
mune cells (e.g. neutrophils, macrophages) [12,28,29],
inflammatory mediators (e.g. interleukin 6, high mobility
group protein B1) [30,31], markers of coagulation/fibrin-
olysis (e.g. protein C, thrombomodulin, and plasma
activator inhibitor-1) [30], and markers of oxidative
stress (thioredoxin 1) [32] are all elevated in patients
with AEx-IPF.
Epithelial cell damage in patients with IPF is demon-
strated by over-expression of matrix metalloproteinase
(MMP)-7 [33], MMP-9 [34], and Krebs von den Lungen-
6 (KL-6) [30]. Accelerated epithelial cell proliferation,
with increases in the proliferation markers CCNA2 and
Ki-67, in patients with AEx-IPF may be a compensatory
response to injury, and is associated with epithelial celldeath [33]. Transforming growth factor (TGF)-beta, a
fibrogenic cytokine, is upregulated in IPF [35], and
galectin-3, a mediator of fibrosis induced by TGF-beta,
is elevated in the lungs and serum of patients with stable
IPF and AEx-IPF [36]. Circulating bone marrow-
derived fibrocytes may also provide a source of lung
fibroblasts and myofibroblasts, as the number of circu-
lating fibrocytes has been shown to be higher in pa-
tients with IPF and AEx-IPF, compared with healthy
subjects [37,38].
Risk factors and precipitating factors for AEx-IPF
An AEx-IPF can occur at any time during the course of
IPF and, for some patients, may be the presenting mani-
festation [1,11,23,39]. Risk factors for AEx-IPF are un-
clear, but there is evidence that a number of factors may
increase risk. Lower total lung capacity, lower forced
vital capacity (FVC) and/or lower diffusing capacity of
the lung for carbon monoxide (DLco) have been shown
to increase the risk of AEx-IPF [3,19], as has a greater
decline in FVC over time [40,41].
A higher degree of dyspnea (score ≥2 on the modified
Medical Research Council dyspnea scale) [40] or of
fibrosis on HRCT [42] has been shown to increase the
risk of AEx-IPF, as has the presence of concomitant con-
ditions such as emphysema [3] or pulmonary hyperten-
sion [43]. However, age does not appear to be an
independent predictor of the risk of an AEx-IPF [6]. In-
vasive examinations such as bronchoscopy [18], bron-
choalveolar lavage (BAL) [11,44,45], and pulmonary
resection for lung cancer [42] can precipitate AEx-IPF,
although these exacerbations may be regarded as com-
plications of these procedures rather than true exacerba-
tions. There is some evidence from a number of small,
retrospective studies that surgical lung biopsy is a pre-
cipitating factor for AEx-IPF; however, the risk of AEx-
IPF from video-assisted thoracoscopic operation appears
to be elevated only in patients with severe physiologic
impairment or substantial comorbidity [46].
GERD, a common comorbidity in patients with IPF,
may contribute to the pathogenesis of IPF through intro-
duction of gastric acid into the respiratory tree
[16,47,48]. In some patients with AEx-IPF, pepsin levels
were found to be elevated in BAL fluid, suggesting a
possible role for GERD in the pathogenesis of AEx-IPF
[47]. There is some evidence to suggest that the treat-
ment of GERD in patients with IPF reduces mortality
rates [49,50].
Impact of AEx-IPF on patients
The latest international guidelines for the management
of IPF state that the occurrence of AEx-IPF is consistent
with disease progression [1]. The precise impact of AEx-
IPF on IPF, such as which and to what extent disease
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AEx-IPF affect the lives of patients with IPF who survive
them, is difficult to determine. However, AEx-IPF are
certainly a leading cause of hospitalization [51] and
death [40,51,52] among patients with IPF. Median sur-
vival after an AEx-IPF has been reported to be between
22 days and 4.2 months [18,19,40]. Reported in-hospital
mortality rates vary widely, between 27% and 96%
[18,19,23,53]. In a retrospective review of 461 patients
with IPF, 96 (21%) patients were hospitalized for AEx-
IPF over a median follow-up period of 22.9 months [19].
Patients with an AEx-IPF had a lower median survival
time than those who had not suffered an AEx-IPF (15.5
months vs. 60.6 months from the diagnosis of IPF) and
lower 5-year survival rates (18.4% vs. 50.0%). There is
some evidence that patients with better lung function
(FVC, PaO2, DLCO) prior to AEx-IPF are more likely to
survive an AEx-IPF [18,54], suggesting that preservation
of lung function may be an important way of reducing
the impact of AEx-IPF in patients with IPF.
Management of AEx-IPF
The latest international treatment guidelines state that
supportive care remains the mainstay of treatment for
AEx-IPF, but also give a weak recommendation for the
treatment of the majority of patients with AEx-IPF with
corticosteroids, based on anecdotal reports of benefit
and the high mortality associated with AEx-IPF [1]. In
clinical practice, the treatment of AEx-IPF is variable.
Corticosteroids (e.g. prednisone, methylprednisolone)
are used in the majority of patients who suffer an AEx-
IPF, usually in pulse doses [9,12,18,28,53]. Preliminary
data suggest that response to high-dose corticosteroid
treatment may depend on the type of HRCT lesion, with
better responses achieved in those with a peripheral
pattern [8]. Broad-spectrum antibiotics and immunosup-
pressants (cyclosporin or cyclophosphamide) are some-
times used in addition to corticosteroids [28].
However, the efficacy of immunosuppressants in the
treatment of AEx-IPF is based on a few small retro-
spective studies that do not provide conclusive evi-
dence for benefit [54-56].
A small prospective clinical trial of anticoagulation in
IPF published in 2005 reported improved survival in the
anticoagulation group, mostly due to reduced mortality
associated with AEx-IPF suggesting the efficacy of
anticoagulation in the treatment of AEx-IPF; however,
debate remained about the benefits of anticoagulation
therapy in patients with IPF due to the small size and
methodological limitations of this study [51]. The ACE-
IPF trial, a randomized, double-blind, placebo-controlled
study of warfarin as a treatment for IPF, was terminated
early on the recommendation of the Data and Safety
Monitoring Board due to higher mortality in thewarfarin arm and a low likelihood of benefit [57] and
the use of anticoagulants in patients with IPF is now
discouraged.
Mechanical ventilation is often used in patients with
AEx-IPF, but the data on its effects on outcomes are mixed
[11,28,30,53,58]. Other treatments for AEx-IPF that have
been investigated in small studies include polymyxin B-
immobilized fiber column (PMX) hemoperfusion [7,59]
and tacrolimus, a cytokine transcription inhibitor [60],
usually administered in addition to corticosteroids.
There is some evidence that delaying the initiation of
treatment following AEx-IPF is associated with worse
mortality rates. In a retrospective review of 37 AEx-IPF
experienced by 27 patients, patients who were discharged
had a significantly shorter delay between admission and
initiation of treatment than those who died in hospital
(mean 3.1 days vs. 6.0 days) [18]. In this study, all of the
patients received oxygen therapy, most received methyl-
prednisolone and antibiotics and some received cyclo-
phosphamide [18].
Reducing the risk of exacerbations
Clinical trials of several investigational treatments for
IPF have evaluated whether chronic treatment of IPF
reduces the incidence of AEx-IPF. A trial of sildenafil, a
phosphodiesterase-5 inhibitor, showed a numerical
reduction in AEx-IPF in patients given sildenafil versus
placebo (3 [3.4%] vs. 7 [7.6%]), but the number of events
was small and the difference was not statistically
significant [61]. In trials of imatinib, a tyrosine kinase in-
hibitor [62], bosentan, an endothelin receptor antagonist
[63], the anticoagulant warfarin [57], and inhaled N-
acetylcysteine [15], numerically higher rates of AEx-IPF
were found in the active treatment arms compared with
the placebo arms. Further, in the PANTHER-IPF trial,
which investigated triple therapy with prednisone, aza-
thioprine, and N-acetylcysteine in patients with IPF, a
significantly higher rate of AEx-IPF was observed in
patients receiving triple therapy versus placebo [17]. In-
deed this arm of the study was terminated prematurely
after a mean follow-up of 32 weeks due to a significantly
higher mortality and hospitalization rates in patients
receiving triple therapy versus placebo [17]. Interferon
gamma-1b showed similar rates of AEx-IPF compared
with placebo in the INSPIRE study, which was prema-
turely terminated due to the absence of a benefit on
mortality [64].
Pirfenidone, an anti-fibrotic molecule that has been li-
censed for the treatment of IPF in Japan, India, China,
Europe, and Canada, but was not approved in the United
States, has shown inconsistent effects on AEx-IPF. A
Phase II study in Japanese patients with IPF was termi-
nated after 9 months of a planned 1-year follow-up
based on a higher frequency of AEx-IPF in the placebo
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However, in a Phase III trial in Japanese patients, no
significant differences were observed in the incidence of
AEx-IPF between patients treated with pirfenidone
(1800 or 1200 mg/day) or placebo for 52 weeks [41].
Pirfenidone was investigated in two 72-week Phase III
randomized, placebo-controlled trials conducted in thir-
teen countries: CAPACITY 1 and CAPACITY 2 [13].
Neither of these studies showed a significant difference
between groups in time to worsening of IPF, the
definition of which included the time to an AEx-IPF,
death, lung transplantation, or admission to hospital for
respiratory problems. An additional Phase III trial of
pirfenidone is ongoing (ASCEND; NCT01366209).
Nintedanib (formerly known as BIBF 1120) is a tyro-
sine kinase inhibitor in clinical development for the
treatment of IPF. In the Phase II, 12-month, random-
ized, placebo-controlled TOMORROW trial, a lower
incidence of AEx-IPF was observed in patients treated
with nintedanib 300 mg/day than placebo (2.4 vs. 15.7
AEx-IPF per 100 patient years) [14]. However, these re-
sults should be interpreted with a degree of caution, as
the incidence of AEx-IPF was a secondary endpoint,
with no adjustment for multiple comparisons, and the
discontinuation rate in the nintedanib 300 mg/day group
was higher than in the placebo group (37.6% vs. 28.2%)
[14]. It is interesting that nintedanib may have an
effect on AEx-IPF whereas the tyrosine kinase inhibitor
imatinib, which inhibits the platelet-derived growth fac-
tor receptor (PDGFR), did not [62]. Nintedanib is an
inhibitor of PDGFR, vascular endothelial growth factor
receptor (VEGFR), and fibroblast growth factor receptor
(FGFR) [65] and this specificity of inhibition may be
key to its effects on AEx-IPF. In pre-clinical studies,
nintedanib has demonstrated anti-fibrotic and anti-
inflammatory effects that may influence the course of
IPF [66,67]. The effect of nintedanib on the progression
of IPF and on AEx-IPF remains to be established and is
being investigated in two ongoing 52-week Phase III
trials (INPULSIS-1 and INPULSIS-2; NCT01335464 and
NCT01335477). In these trials, the criteria used to diagnose
AEx-IPF are similar to those defined by the IPF Clinical
Research Network [6] and cases of suspected AEx-IPF will
be adjudicated by an independent committee.
Finally, a recent study using prospective data from
242 patients in the placebo groups of three randomized
clinical trials showed that patients who used anti-acid
treatments (proton-pump inhibitors or histamine-
receptor-2 blockers) at baseline had fewer AEx-IPF
than those not taking such treatments at baseline (zero
vs. nine events after a mean follow-up of 30 weeks)
[68]. The authors hypothesized that anti-acid treat-
ment might decrease the frequency of AEx-IPF by re-
ducing the acidity of the microaspirate and suggestedthat controlled clinical trials of anti-acid treatments
are needed.
Conclusions
IPF is a progressive disease and all patients will deterior-
ate over time. However, IPF has a highly variable disease
course. Some patients with IPF suffer AEx-IPF, which
are associated with high morbidity and mortality and a
worsened prognosis. The methodology used to define
AEx-IPF has varied across studies, making it difficult to
form an accurate understanding of the incidence and
clinical implications of AEx-IPF. More data are needed
on the impact of AEx-IPF on patients with IPF. Current
treatments for AEx-IPF have only limited data to sup-
port their effectiveness and supportive therapy remains
the mainstay of care. There is emerging evidence that
chronic treatment of IPF may reduce the risk of AEx-
IPF and clinical trials investigating this are underway.
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